It is estimated that 1 in 3 people are currently infected with Human Papilloma Virus (HPV), with a lifetime prevalence of around 80-90%. There are over 100 different types of HPV, these are generally divided into high-risk and low-risk strains.
Over 95% of cervical cancers are caused by an infection with a high-risk strain of HPV. These include HPV 16 and 18, which are responsible for around 70% of cervical cancers. Other high-risk strains include HPV 31, 33, 45, 52, 58. Infection with HPV is responsible for several other cancers too.
It is estimated that 1 in 3 people are currently infected with Human Papilloma Virus (HPV), with a lifetime prevalence of around 80-90%. There are over 100 different types of HPV, these are generally divided into high-risk and low-risk strains.
Over 95% of cervical cancers are caused by an infection with a high-risk strain of HPV. These include HPV 16 and 18, which are responsible for around 70% of cervical cancers. Other high-risk strains include HPV 31, 33, 45, 52, 58. Infection with HPV is responsible for several other cancers too.
Have you been diagnosed with HPV? Sign up to be the first to find out when the Hupela-HPV programme launches:
Have you been diagnosed with HPV? Sign up to be the first to find out when the Hupela-HPV programme launches:
If infection with a high-risk strain of HPV is not cleared – over time this can lead to abnormal cellular changes on the cervix (this is called cervical intraepithelial neoplasia (or CIN), also referred to as cervical dysplasia), and in the longer term may cause cervical cancer.
There is currently no known medical cure for HPV. The only effective response is a strong immune system. With age, the immune system is increasingly weakened and may no longer be able to effectively fight HPV infection on its own.
Recent evidence from two randomised, placebo-controlled clinical trials (one completed and one phase II randomised, double-blind placebo-controlled, crossover trial is ongoing) have shown that it is possible to eradicate infection with a high-risk strain of HPV with a natural supplement derived from the mycelium roots of shiitake mushrooms, called AHCC (or Active Hexose Correlated Compound). This substance is thought to support the body’s natural defenses by strengthening the immune system.
Hupela is currently developing a treatment pathway with AHCC for women with high-risk strains of HPV, who may be at risk of developing, or have already developed, abnormal cervical cells.
If you would like to know more about the AHCC programme for HPV, you can sign up for more information:
The programme includes supplementation with a natural substance . The evidence for its efficacy is compelling, with numerous clinical trials showing its immuno-modulating effects.
For HPV, there have been two clinical trials in the US demonstrating the efficacy of AHCC in eradicating high-risk HPV in the long term (one completed and one phase II randomised, double-blind placebo-controlled, crossover trial is ongoing).
We are collaborating with the Japanese company, Amino Up, who have developed AHCC and their exclusive European distributor, to provide AHCC to the UK market in the targeted treatment of HPV at an affordable price.
If followed correctly, this treatment has been shown to eradicate up to 70% of high-risk HPV cases over a 3-month period and in the long-term (at least 12 months after termination of treatment).
We offer this treatment plan in 3 tiers to suit different needs and wallets. This includes a Basic Plan, for women who just want access to the supplementation regimen.
Advanced Plan
AHCC x 3 months
Access to free HPV Educational Programme
HPV testing service before and after treatment (able to detect which of two high-risk groups your strain falls into)
Precision Plan
AHCC x 3 months
Access to free HPV Educational Programme
HPV testing service before and after treatment (able to detect the specific high-risk strain you have)
Immune marker service (incl. natural killer or NK cells) to determine optimal treatment length and to track your progress over the treatment period
How are we different?
We are the only organisation to offer the official and patented AHCC product* to the UK market in the targeted treatment of HPV.
In addition, we also offer a comprehensive testing service for women who want to have a more personalised service and be able to track their treatment progress.
We offer all of this at a highly competitive price because we want as many women to benefit from the treatment as possible.
We have also developed a unique Education Programme to raise awareness about HPV and cervical cancer, which we provide free of charge with all treatment plans.
*This is the only product tested in multiple clinical trials and shown specifically to eradicate high-risk HPV infection for the long-term.